Exo Therapeutics

Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.

Exo Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $2.5B in funding across 24 round(s). With a team of 11-50 employees, Exo Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Exo Therapeutics, raised $78.0M. Discover more about their projects, partnerships, and impact on our platform.